109 related articles for article (PubMed ID: 16626757)
1. Interferons and cognition.
Montalban X; Rio J
J Neurol Sci; 2006 Jun; 245(1-2):137-40. PubMed ID: 16626757
[TBL] [Abstract][Full Text] [Related]
2. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
Flechter S; Vardi J; Finkelstein Y; Pollak L
Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
[TBL] [Abstract][Full Text] [Related]
3. [Combined therapy in multiple sclerosis].
García-Merino JA; Blasco-Quítez MR; Ortiz-Benítez P; Puerta C
Rev Neurol; 2003 Mar 16-31; 36(6):545-9. PubMed ID: 12652419
[TBL] [Abstract][Full Text] [Related]
4. Beta interferons for multiple sclerosis.
Med Lett Drugs Ther; 2002 Oct; 44(1141):88-9. PubMed ID: 12381969
[No Abstract] [Full Text] [Related]
5. [Multiple sclerosis. Not only gait, but thinking is also affected].
MMW Fortschr Med; 2002 May; Suppl 2():86. PubMed ID: 12070865
[No Abstract] [Full Text] [Related]
6. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
7. Cognitive dysfunction in multiple sclerosis: the effect of pharmacological interventions.
Lyros E; Messinis L; Papageorgiou SG; Papathanasopoulos P
Int Rev Psychiatry; 2010; 22(1):35-42. PubMed ID: 20222786
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying therapy in multiple sclerosis: update and clinical implications.
Goodin DS
Neurology; 2008 Dec; 71(24 Suppl 3):S8-13. PubMed ID: 19064873
[TBL] [Abstract][Full Text] [Related]
9. Early treatment of multiple sclerosis to prevent neurologic damage.
Coyle PK
Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
[TBL] [Abstract][Full Text] [Related]
10. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
Kieseier BC; Hartung HP
Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
[No Abstract] [Full Text] [Related]
11. Biologic role of interferon beta in multiple sclerosis.
Billiau A; Kieseier BC; Hartung HP
J Neurol; 2004 Jun; 251 Suppl 2():II10-4. PubMed ID: 15264107
[TBL] [Abstract][Full Text] [Related]
12. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
Gout O
Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
[No Abstract] [Full Text] [Related]
13. Interferon after 10 years in patients with multiple sclerosis.
Pozzilli C; Prosperini L; Sbardella E; Paolillo A
Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
[TBL] [Abstract][Full Text] [Related]
14. Are there protective treatments for cognitive decline in MS?
Amato MP; Portaccio E; Zipoli V
J Neurol Sci; 2006 Jun; 245(1-2):183-6. PubMed ID: 16643949
[TBL] [Abstract][Full Text] [Related]
15. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
16. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
17. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
Thrower BW
Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
[TBL] [Abstract][Full Text] [Related]
19. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
20. Summary: Registry data.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S39-41. PubMed ID: 21205682
[No Abstract] [Full Text] [Related]
[Next] [New Search]
